Don't Just Read the News, Understand It.
Published loading...Updated

Donald Trump’s drug plan risks higher medicine prices in Europe

  • On May 12, 2025, U.S. President Donald Trump issued an Executive Order directing Health and Human Services to enforce Most-Favored-Nation drug pricing rules based on the lowest prices in comparable wealthy countries.
  • This policy seeks to lower the cost of medications in the United States by aligning U.S. drug prices with those charged in countries whose GDP per capita reaches at least 60 percent of the American level, addressing the fact that drug prices in the U.S. are substantially higher than in many other OECD countries.
  • Industry experts warn this plan pressures European health systems to raise drug prices, potentially limiting access to new treatments amid resistance due to stretched budgets and strict national pricing controls.
  • Dustin Benton suggested that higher drug prices in Europe could allow for lower costs in the United States, while Richard Torbett described the policy as confirmation of long-standing concerns that the UK’s low drug prices may deter investment.
  • The order risks reducing U.S. innovation funding and GDP growth, faces legal challenges, and may trigger drugmakers to seek higher prices in Europe to offset reduced U.S. revenues.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
2
Center
3
Right
1
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Financial Times broke the news in London, United Kingdom on Monday, June 23, 2025.
Sources are mostly out of (0)